The estimated Net Worth of Yat Sun Or is at least $13.9 Milione dollars as of 5 December 2023. Yat Or owns over 2,412 units of Enanta Pharmaceuticals Inc stock worth over $4,463,168 and over the last 11 years he sold ENTA stock worth over $7,827,501. In addition, he makes $1,630,810 as Senior Vice President - Research & Development e Chief Scientific Officer at Enanta Pharmaceuticals Inc.
Yat has made over 26 trades of the Enanta Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 2,412 units of ENTA stock worth $23,228 on 5 December 2023.
The largest trade he's ever made was exercising 129,087 units of Enanta Pharmaceuticals Inc stock on 3 January 2014 worth over $94,234. On average, Yat trades about 10,753 units every 67 days since 2013. As of 5 December 2023 he still owns at least 370,695 units of Enanta Pharmaceuticals Inc stock.
You can see the complete history of Yat Or stock trades at the bottom of the page.
Dr. Yat Sun Or, Ph.D. is Senior Vice President - Research & Development, Chief Scientific Officer of the Company. Prior to joining Enanta, Dr. Or held key leadership positions at Abbott Laboratories from 1985 to 1999, where he received two Chairman’s Awards for his outstanding research, which led to the discovery and development of immunosuppressant and antibacterial drugs. Prior to Abbott, Dr. Or was a member of the cardiovascular drug discovery team at Schering-Plough. Dr. Or received his Ph.D. in Organic Chemistry from the University of Chicago and completed Postdoctoral Fellowships at Ohio State University and Indiana University.
As the Senior Vice President - Research & Development e Chief Scientific Officer of Enanta Pharmaceuticals Inc, the total compensation of Yat Or at Enanta Pharmaceuticals Inc is $1,630,810. There are 1 executives at Enanta Pharmaceuticals Inc getting paid more, with Jay Luly having the highest compensation of $4,483,500.
Yat Or is 67, he's been the Senior Vice President - Research & Development e Chief Scientific Officer of Enanta Pharmaceuticals Inc since 1999. There are 2 older and 12 younger executives at Enanta Pharmaceuticals Inc. The oldest executive at Enanta Pharmaceuticals Inc is Bruce Carter, 76, who is the Independent Non-Executive Chairman of the Board.
Yat's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.
Over the last 12 years, insiders at Enanta Pharmaceuticals Inc have traded over $72,640,961 worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth $5,071,651 . The most active insiders traders include Jay R. Luly, V Life Science Ventures Gmb... e Yat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $285,155. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth $190,762.
enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include: